We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Merck Millipore Announces Opening of its GMP Bioproduction Facility in France
News

Merck Millipore Announces Opening of its GMP Bioproduction Facility in France

Merck Millipore Announces Opening of its GMP Bioproduction Facility in France
News

Merck Millipore Announces Opening of its GMP Bioproduction Facility in France

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Merck Millipore Announces Opening of its GMP Bioproduction Facility in France"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Merck Millipore has announced the opening of its advanced GMP bioproduction facility in Martillac, France, offering a full, single-use process train to speed a molecule's journey to the clinic.

The site will serve users of Merck Millipore's Provantage™ Biodevelopment and Clinical Supply Solutions, an innovative, "open source" manufacturing option that incorporates the latest technologies for upstream and downstream processes.

The open source approach provides customers with greater control over production.

With a traditional outsourcing model, the customer's process must fit the facility and the contract manufacturer controls the process.

With ProVantage™ Solutions, Merck Millipore develops the process for further use by the customer.

At the new facility, Merck Millipore provides access to proven technologies, process development expertise and validation services, offering a robust template that makes it possible to go from clone selection to GMP product in only 12 months.

The facility offers GMP production of mammalian proteins for pre-clinical to phase II production at the 50 L to 1,250 L scale.

For phase III and commercial production, customers can transfer manufacturing to any location, at any scale.

This freedom brings enhanced flexibility to the molecule development and the manufacturing process.

"Merck Millipore leverages more than 25 years of biomanufacturing experience with 150 molecules in our new facility in France," said Christophe Couturier, Vice President of Services and Solutions, Merck Millipore.

Couturier continued, "As the basis for Provantage™ Solutions, our experts complement customers' internal capabilities in a way that combines the best of in-house production and conventional outsourcing. The end result is increased productivity and an accelerated time to market."

For more information on the new facility and Provantage™ Solutions, please visit www.merckmillipore.com/provantage.

Advertisement